Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #100432 on NanoViricides Inc. (NNVC)
changes_iv
10/01/14 7:35 AM
#100456 RE: robi-1-kenobi #100432
In July 2010, our collaborators at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) presented the data on evaluation of anti-Ebola/Marburg nanoviricides. Significant efficacy was reported to have been achieved in cell culture studies. Animal studies indicated improvement in lifetime in the uniformly lethal mouse model. Further improvement in chemistry and dosage levels may be expected to lead to significant survival.
In September 2014, we announced that we have already completed design of novel anti-Ebola drug candidates, based on “in silico” or molecular modeling approach, and synthesis has also begun. We believe that we will be able to work with our previous collaborators at the USAMRIID, and also at the NIH, to begin testing the potential utility of these drug candidates in cell cultures and animal models soon.
To date, we have entered into the following collaborations. Cooperative Research and Development Agreement for Material Transfer, dated October 15, 2007, between NanoViricides, Inc. and United States Army Medical Research Institute of Infectious Disease (“Laboratory”). The term of the agreement was for one year initially and extended for an additional year. It has been extended again, based on positive results. The Company shall invent, develop, and provide to the laboratory, Nanoviricides® that are expected to be capable of attacking a multiplicity of different Ebola and Marburg viruses. The Laboratory shall assess in vitro and in vivo activity of the anti-Ebola Nanoviricides® provided against the virus. There is no payment by the Company to the Laboratory, nor from the Laboratory to the Company. USAMRIID has federal funding to support their part of the work.